Research
Hormonal
Tirzepatide use is associated with rare but serious hypersensitivity reactions, including anaphylaxis and angioedema, occurring in approximately 1-4% of patients, often linked to anti-drug antibodies but not always causally related.
Watch for signs of a severe allergic reaction, such as swelling of the face/throat, difficulty breathing, or widespread hives. These are rare but serious. If you experience them, seek emergency medical help immediately. Most skin reactions are mild and go away on their own.
GoodSupportsHIGH confidence
Across the SURPASS studies, hypersensitivity reactions occurred in approximately 1%-2% of tirzepatide-treated patients... In immunogenicity analysis study by Mullin et al... the rate was somewhat higher (~3-4%), with greater incidence in antibody-positive patients (4.1% vs. 3.0% in antibody-negative)... severe allergic reactions, including anaphylaxis and serum sickness-like cutaneous and systemic symptoms, have been linked to tirzepatide.
Why this rating
Based on Phase 3 trials and FDA warnings.
Source
Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications – A comprehensive review
Heba Saed El‐Amawy · Anais Brasileiros de Dermatologia · 2025
DOI 10.1016/j.abd.2025.501255
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide administration (2.5-15 mg weekly) causes injection-site reactions (ISRs) in 2-8% of patients, presenting as localized erythema, swelling, or pruritus, which are generally mild, self-limiting, and comparable in frequency to other GLP-1 agonists.Good
- Rapid and significant weight loss induced by Tirzepatide leads to aesthetic changes, including facial volume loss ('Ozempic face'), skin laxity, and altered collagen structure, which are secondary to fat loss rather than direct drug toxicity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →